Essential thrombocythemia

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Anagrelide (Agrylin)

Regimen #1, Harrison et al. 2005

• Anagrelide (Agrylin) 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
• Aspirin 75 mg (100 mg in Australia) PO once daily

Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)

• Anagrelide (Agrylin) 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal (≤450 x 10⁹/L) or close to normal levels (>450 x 10⁹/L to 600 x 10⁹/L)")
• Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed
2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. link to original article contains verified protocol PubMed

Hydroxyurea (Hydrea)

Regimen #1, Harrison et al. 2005

• Hydroxyurea (Hydrea) 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
• Aspirin 75 mg (100 mg in Australia) PO once daily

Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)

• Hydroxyurea (Hydrea) 1500 mg PO once daily ("increased until maintenance of the platelet count at normal (≤450 x 10⁹/L) or close to normal levels (>450 x 10⁹/L to 600 x 10⁹/L)")
• Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed
2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. link to original article contains verified protocol PubMed